Edition:
United States

Halozyme Therapeutics Inc (HALO.OQ)

HALO.OQ on NASDAQ Stock Exchange Global Select Market

17.53USD
21 Sep 2018
Change (% chg)

$0.27 (+1.56%)
Prev Close
$17.26
Open
$17.30
Day's High
$17.64
Day's Low
$17.30
Volume
1,105,082
Avg. Vol
287,948
52-wk High
$21.47
52-wk Low
$16.06

Chart for

About

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company's segment also includes research and development activities and product sales of Hylenex... (more)

Overall

Beta: 1.82
Market Cap(Mil.): $2,529.65
Shares Outstanding(Mil.): 144.30
Dividend: --
Yield (%): --

Financials

  HALO.OQ Industry Sector
P/E (TTM): 36.50 108.33 32.69
EPS (TTM): 0.48 -- --
ROI: 25.24 1.50 12.72
ROE: 48.73 0.19 14.85

BRIEF-Halozyme Reports Q1 Loss Per Share $0.19

* Q1 EARNINGS PER SHARE VIEW $-0.22 -- THOMSON REUTERS I/B/E/S

May 10 2018

BRIEF-Halozyme Therapeutics Says CEO Helen Torley's 2017 Compensation Was $5.18 Mln ‍​

* HALOZYME THERAPEUTICS INC SAYS CEO HELEN I. TORLEY'S 2017 TOTAL COMPENSATION WAS $5.18 MILLION VERSUS $4.85 MILLION IN 2016 – SEC FILING‍​ Source text - https://bit.ly/2udFEM8 Further company coverage:

Mar 22 2018

Competitors

  Price Chg
Novo Nordisk A/S (NOVOb.CO) kr.301.50 +3.00
Sanofi SA (SASY.PA) €74.50 -0.17
Eli Lilly And Co (LLY.N) $106.33 +0.26
Albireo Pharma Inc (ALBO.OQ) $31.44 -1.26
MannKind Corporation (MNKD.OQ) $1.74 +0.06

Earnings vs. Estimates